Crinetics Pharmaceuticals, Inc. (CRNX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 9M 18M 27M Q1 '17: 45K Q2 '17: 832K Q3 '17: 640K Q4 '17: 528K Q1 '18: 442K Q2 '18: 657K Q3 '18: 548K Q4 '18: 781K Q1 '19: 367K Q2 '19: 0 Q3 '19: 505K Q4 '19: 321K Q1 '20: 71K Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 3.1M Q2 '22: 439K Q3 '22: 458K Q1 '23: 2.7M Q2 '23: 988K Q3 '23: 346K Q4 '23: 0 Q1 '24: 640K Q2 '24: 399K Q3 '24: 0 Q4 '24: 0 Q1 '25: 361K Q2 '25: 1M Q3 '25: 143K Q4 '25: 6.2M Q1 '26: 10.7M Q2 '26: 25.1M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 9M 18M 27M Q1 '25: 361K Q2 '25: 1M Q1 '26: 10.5M Q2 '26: 25M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q1 '17: -2.6M Q2 '17: -1.6M Q3 '17: -2.4M Q4 '17: -2.5M Q1 '18: -5.5M Q2 '18: -5.7M Q3 '18: -8.1M Q4 '18: -9.4M Q1 '19: -10M Q2 '19: -13.3M Q3 '19: -15.2M Q4 '19: -15.2M Q1 '20: -17.8M Q2 '20: -16.9M Q3 '20: -18.5M Q4 '20: -21.8M Q1 '21: -22.9M Q2 '21: -26.1M Q3 '21: -27.8M Q4 '21: -30.9M Q1 '22: -33.8M Q2 '22: -43M Q3 '22: -43.5M Q4 '22: -47.6M Q1 '23: -48M Q2 '23: -53M Q3 '23: -59M Q4 '23: -62.7M Q1 '24: -73.5M Q2 '24: -82.8M Q3 '24: -87.8M Q4 '24: -94.7M Q1 '25: -111.4M Q2 '25: -129.1M Q3 '25: -142.6M Q4 '25: -133.7M Q1 '26: -140.4M Q2 '26: -132.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q1 '17: -2.6M Q2 '17: -1.6M Q3 '17: -2.4M Q4 '17: -2.5M Q1 '18: -5.5M Q2 '18: -5.6M Q3 '18: -7.6M Q4 '18: -8.5M Q1 '19: -9M Q2 '19: -12.4M Q3 '19: -14.4M Q4 '19: -14.5M Q1 '20: -17.4M Q2 '20: -16.5M Q3 '20: -18.3M Q4 '20: -21.6M Q1 '21: -22.9M Q2 '21: -26.1M Q3 '21: -27.9M Q4 '21: -30.8M Q1 '22: -34.6M Q2 '22: -42.4M Q3 '22: -41.9M Q4 '22: -45M Q1 '23: -46M Q2 '23: -51M Q3 '23: -57.5M Q4 '23: -60.1M Q1 '24: -66.9M Q2 '24: -74.1M Q3 '24: -76.8M Q4 '24: -80.6M Q1 '25: -96.8M Q2 '25: -115.6M Q3 '25: -130.1M Q4 '25: -122.8M Q1 '26: -127.8M Q2 '26: -120.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 70K 140K 210K Q1 '25: 0 Q2 '25: 0 Q1 '26: 200K Q2 '26: 154K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '17: -2.4M Q4 '17: -2.5M Q1 '18: -3.4M Q2 '18: -4.3M Q3 '18: -5.7M Q4 '18: -6M Q1 '19: -6.8M Q2 '19: -12.6M Q3 '19: -13.6M Q4 '19: -13.4M Q1 '20: -12.2M Q2 '20: -15.9M Q3 '20: -18M Q4 '20: -15.9M Q1 '21: -20.1M Q2 '21: -19.9M Q3 '21: -25.7M Q4 '21: -22.9M Q1 '22: -13.5M Q2 '22: -28M Q3 '22: -38.5M Q4 '22: -35.2M Q1 '23: -40.7M Q2 '23: -45.7M Q3 '23: -41.3M Q4 '23: -40.8M Q1 '24: -52.9M Q2 '24: -47.6M Q3 '24: -62.8M Q4 '24: -66.9M Q1 '25: -88.5M Q2 '25: -85.9M Q3 '25: -110.7M Q4 '25: -92.9M Q1 '26: -124.7M Q2 '26: -94.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '17: -2.5M Q4 '17: -2.7M Q1 '18: -3.5M Q2 '18: -4.8M Q3 '18: -5.9M Q4 '18: -6.3M Q1 '19: -7.2M Q2 '19: -12.6M Q3 '19: -13.6M Q4 '19: -13.5M Q1 '20: -12.3M Q2 '20: -15.9M Q3 '20: -18.1M Q4 '20: -16M Q1 '21: -20.2M Q2 '21: -20.1M Q3 '21: -25.8M Q4 '21: -22.9M Q1 '22: -13.6M Q2 '22: -28.6M Q3 '22: -39.2M Q4 '22: -35.5M Q1 '23: -40.7M Q2 '23: -46M Q3 '23: -44.8M Q4 '23: -41.7M Q1 '24: -54.2M Q2 '24: -48.6M Q3 '24: -63.4M Q4 '24: -67.9M Q1 '25: -89.7M Q2 '25: -89.1M Q3 '25: -111.6M Q4 '25: -93.4M Q1 '26: -125.5M Q2 '26: -94.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q2 '21: 37.1M Q3 '21: 38.3M Q1 '22: 47.7M Q2 '22: 52.5M Q3 '22: 53.8M Q1 '23: 53.9M Q2 '23: 54.3M Q3 '23: 56.8M Q1 '24: 72.3M Q2 '24: 79M Q3 '24: 80.1M Q1 '25: 93.1M Q2 '25: 93.8M Q3 '25: 94.2M Q1 '26: 104.1M Q2 '26: 105.6M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '17: -6.75 Q1 '18: -7.49 Q2 '18: -8.68 Q3 '18: -7.39 Q4 '18: -6.06 Q1 '19: -3.51 Q2 '19: -1.61 Q3 '19: -1.83 Q4 '19: -2.08 Q1 '20: -2.42 Q2 '20: -2.44 Q3 '20: -2.40 Q4 '20: -2.46 Q1 '21: -2.44 Q2 '21: -2.61 Q3 '21: -2.78 Q4 '21: -2.79 Q1 '22: -2.83 Q2 '22: -2.94 Q3 '22: -2.99 Q4 '22: -3.15 Q1 '23: -3.27 Q2 '23: -3.40 Q3 '23: -3.63 Q4 '23: -3.68 Q1 '24: -3.76 Q2 '24: -3.76 Q3 '24: -3.71 Q4 '24: -3.70 Q1 '25: -3.81 Q2 '25: -4.10 Q3 '25: -4.52 Q4 '25: -4.94 Q1 '26: -5.13 Q2 '26: -5.04 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.